Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.71−1.02 (-3.70%)
Close on Nov 20, 2026Market cap $4.64BP/E –Yield –
Cogent Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cogent Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$309.24M. For fiscal 2025 it was -$266.00M. The highest annual figure on record is -$26.75M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$266.00M | – |
| FY2024 | Dec 31, 2024 | -$208.36M | – |
| FY2023 | Dec 31, 2023 | -$156.42M | – |
| FY2022 | Dec 31, 2022 | -$125.50M | – |
| FY2021 | Dec 31, 2021 | -$60.48M | – |
| FY2019 | Dec 31, 2019 | -$41.55M | – |
| FY2018 | Dec 31, 2018 | -$33.04M | – |
| FY2017 | Dec 31, 2017 | -$26.75M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$77.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$87.33M | – |
| Q4 FY2025 | Dec 31, 2025 | -$79.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$64.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.67M | – |
| Q1 FY2025 | Mar 31, 2025 | -$67.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$60.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$52.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$52.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$44.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.38M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.27M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.46M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.19M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.56M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.02M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.30M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.06M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.62M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.98M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.59M | – |
See a number that looks wrong?